Michael Hunt, CFO of ReNeuron Group Plc (LON:RENE) tells Proactive they've received positive guidance from the US regulator as they prepare to take their CTX cell therapy candidate for stroke victims into final-stage clinical trials.
ReNeuron 'greatly encouraged' by US regulator feedback on CTX cell therapy trial
Quick facts: ReNeuron Group PLC
Price: 92.551 GBX
Market Cap: £29.5 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ReNeuron Group PLC named herein, including the promotion by the Company of ReNeuron Group PLC in any Content on the Site, the Company receives...FOR OUR FULL DISCLAIMER CLICK HERE